Article: The Sensory Environment Is Part of Cancer Care
The Sensory Environment Is Part of Cancer Care
The Sensory Environment Is Part of Cancer Care
Why understanding smell, taste, and appetite matters in oncology supportive care
Cancer treatment changes more than the disease it is intended to treat. It can also change how patients experience the world around them.
A familiar meal may become unappealing. Foods that were once enjoyable may acquire an unpleasant taste. Ordinary cooking odors may become difficult to tolerate. Some patients experience reduced sensitivity to smell, while others report heightened sensitivity or aversion to particular odors.
These changes can affect comfort, eating behavior, and quality of life.
For clinicians, they raise an important question: How should the sensory environment be considered when caring for patients whose biological responses to familiar stimuli may have changed?
Smell and taste are not peripheral to nutrition
The experience of eating involves several interacting sensory systems. Taste receptors detect basic taste qualities, while olfaction contributes substantially to the complex experience of flavor. Texture, temperature, oral sensations, memory, and expectation also influence whether food is appealing.
Cancer and its treatments can disrupt these relationships.
A systematic review and meta-analysis published in the European Journal of Oncology Nursing in February 2025 examined 30 studies involving 15,722 patients. The researchers estimated that chemotherapy-induced taste alterations affected approximately 70% of patients, although prevalence varied considerably across studies.
Dry mouth, oral mucositis, and repeated chemotherapy cycles were among the factors associated with increased risk. Importantly, this estimate concerned taste alterations, not smell dysfunction.
The consequences may extend beyond the sensory experience itself. When eating becomes unpleasant, patients may avoid particular foods, consume less, or struggle to maintain adequate nutrition.
But the relationship between sensory change and food intake is not always straightforward.
What research in advanced cancer reveals
A 2023 study published in Supportive Care in Cancer examined taste and smell disturbances among patients with advanced cancer receiving care at 11 palliative care centers.
Of the 343 patients included in the analysis, 35.6% reported taste disturbances and 20.9% reported smell disturbances.
Researchers found that greater disturbances in these senses were associated with poorer dietary intake and lower scores on a measure of appetite- and cachexia-related quality of life, even after accounting for performance status and cancer cachexia.
The study was observational. It demonstrated associations, not that sensory dysfunction directly caused reduced intake or that correcting it would necessarily improve nutrition.
A separate 2019 scoping review found a more complicated picture. Across 11 studies measuring sensory function and food behavior, altered taste function—particularly reduced sensitivity to sweetness—was associated with changes in appetite and nutrient intake in some studies. Objective smell measurements, however, did not show a consistent relationship with food behavior in the available evidence.
These findings are not necessarily contradictory. They reflect differences in patient populations, measurement methods, and the distinction between reported sensory difficulties and objectively measured sensory function.
Together, they point toward a need for more precise investigation.
The importance of distinguishing appetite from cachexia
Reduced appetite, altered food enjoyment, and cancer cachexia are related clinical concerns, but they are not interchangeable.
Cancer cachexia is a complex syndrome involving metabolic alterations, inflammation, and loss of skeletal muscle. Its underlying mechanisms cannot be adequately explained by diminished appetite or unpleasant food experiences alone.
The European Society for Medical Oncology recommends multidisciplinary assessment and management of cachexia, including nutritional support and attention to symptoms and metabolic factors.
This distinction is particularly important when considering sensory approaches.
An intervention that makes eating more comfortable would not necessarily reverse the underlying metabolic and inflammatory processes responsible for cachexia.
Nevertheless, improving a patient’s sensory experience may still be a meaningful supportive-care objective.
Comfort, food enjoyment, dietary tolerance, and quality of life are legitimate outcomes, provided they are evaluated independently and not confused with treatment of the underlying syndrome.
Sometimes the appropriate intervention is less scent
In discussions of aromatherapy, the objective is often assumed to be introducing a pleasant fragrance.
Oncology care illustrates why that assumption is incomplete.
For a patient experiencing heightened sensitivity or odor-triggered nausea, reducing unwanted environmental exposure may be more useful than adding another aromatic stimulus.
The American Cancer Society advises patients troubled by food odors to consider measures such as serving foods cold or at room temperature, improving ventilation, and limiting exposure to cooking smells. It also encourages patients to report sensory changes and eating difficulties to their care teams.
These recommendations suggest a broader principle: olfactory care begins with understanding the receiver.
A molecular stimulus that is welcome in one circumstance may be unpleasant in another. The patient’s current condition, previous experience, and surrounding environment can influence the response.
This is one reason that scent delivery in healthcare deserves careful consideration. Personal, controlled exposure allows a different approach from continuous fragrance distribution throughout a shared space.
Neither approach should be presumed clinically superior without evidence appropriate to its intended application.
What should an olfactory study measure?
If olfactory interventions are to contribute meaningfully to supportive care, the research questions must be specific.
An investigation of food enjoyment should not be treated as equivalent to a study of caloric intake. A reduction in self-reported nausea is different from an increase in appetite. Changes in odor preference do not necessarily demonstrate changes in nutritional status.
A useful clinical protocol might therefore evaluate the patient’s initial sensory condition, the composition and delivery of the molecular stimulus, the timing and duration of exposure, and outcomes appropriate to the intended purpose.
It may also be important to distinguish patients with reduced olfactory sensitivity from those experiencing heightened sensitivity, altered odor perception, or learned aversions.
The objective is not to assume that one formulation produces a universal response. It is to determine whether a defined intervention produces a useful and reproducible result under identifiable conditions.
Understanding the patient before introducing the stimulus
At Aeroscena, our work with natural olfactory formulations and clinical delivery systems has reinforced the importance of understanding the relationship between molecular exposure and biological response.
Olfaction is a continuous biological input channel that influences how humans perceive, feel, think, and function.
But that input does not arrive in an unchanging organism.
Illness, treatment, previous experience, and the patient’s immediate physiological condition can alter how environmental information is received and interpreted.
In oncology, this means that a responsible approach to olfactory care may involve reducing unwanted odors, carefully selecting an optional personal intervention, or investigating whether a defined stimulus can improve a particular symptom.
Each requires a different clinical rationale.
The opportunity is not simply to make the treatment environment smell better.
It is to understand how environmental molecular information interacts with the patient’s condition—and whether that understanding can improve the experience of care.
Scientific references for publication
- Zhang B, et al. “Prevalence and risk factors of chemotherapy-induced taste alterations among cancer patients: A systematic review and meta-analysis.” European Journal of Oncology Nursing, February 2025. PubMed.
- Otani H, et al. “Impact of taste/smell disturbances on dietary intakes and cachexia-related quality of life in patients with advanced cancer.” Supportive Care in Cancer, January 30, 2023. PubMed.
- “Chemosensory Changes from Cancer Treatment and Their Effects on Patients’ Food Behavior: A Scoping Review.” Nutrients, September 24, 2019. Full text.
- Arends J, et al. “Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines.” ESMO Open, June 2021. Full text.
- American Cancer Society. “Taste and Smell Changes,” medically reviewed guidance, revised June 26, 2024. Clinical guidance.

